| 摘要 |
A UGT2B inhibitor capable of increasing the bio-availability of a drug, is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: capillarisin, isorhamnetin,β-naphthoflavone, α-naphthoflavone, hesperetin, terpineol, (+)-limonene, β-myrcene, swertiamarin, eriodictyol, cineole, apigenin, baicalin, ursolic acid, isovitexin, lauryl alcohol, puerarin, trans-cinnamaldehyde, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin, gallic acid, genistein, glycyrrhizin, protocatechuic acid, ethyl myristate, umbelliferone, PEG (Polyethylene glycol) 400, PEG 2000, PEG 4000, Tween 20, Tween 60, Tween 80, BRIJ® 58, BRIJ® 76, Pluronic® F68, Pluronic® F127, and a combination thereof. A UGT2B enhancer capable of enhancing a clearance rate of morphine-like analgesic agents, is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: nordihydroguaiaretic acid, wogonin, trans-cinnamic acid, baicalein, quercetin, daidzein, oleanolic acid, homoorientin, hesperetin, narigin, neohesperidin, (+)-epicatechin, hesperidin, liquiritin, eriodictyol, formononetin, quercitrin, genkwanin, kaempferol, isoquercitrin, (+)-catechin, naringenin, daidzin, (−)-epicatechin, luteolin-7-glucoside, ergosterol, rutin, luteolin, ethyl myristate, apigenin, 3-phenylpropyl acetate, umbelliferone, glycyrrhizin, protocatechuic acid, poncirin, isovitexin, 6-gingerol, cineole, genistein, trans-cinnamaldehyde, and a combination thereof. |
| 主权项 |
1. A pharmaceutical composition capable of increasing a bio-availability of morphine-like analgesic agents, including:
an active ingredient as an Uridine diphosphate (UDP)-glucuronosyltransferases 2B (UGT2B) inhibitor that is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: swertiamarin, ursolic acid, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin, gallic acid, glycyrrhizin, protocatechuic acid, ethyl myristate, PEG (Polyethylene glycol) 400, PEG 2000, PEG 4000, Tween 20, Tween 60, polyoxyethylene acyl ether (BRIJ 58), polyoxyethylene 10 stearyl ether (BRIJ 76), Polyethylene-Polypropylene Glycol (Pluronic F68), and Poloxamer 407 (Pluronic F127); a pharmaceutically effective amount of morphine-like analgesic agents including at least one selected from the group consisting of: naloxone, nalorphine, oxymorphone, hydromorphone, dihydromorphine, codeine, naltrindole, nalbuphine and buprenorphine; and a pharmaceutically acceptable inert ingredient. |
